

EQA round: APLA1/24 - Antiphospholipid Antibodies

Deadline: 15.3.2024

Setup: all data

AV = assigned value

N_{tot} = total number of the resultsN_{eva} = number of the results assessed

CVP = consensus of all participants

N_{rel} = relative number of the resultsN_{suc} = number of successful results

>>> ... expected result

S_{rel} = relative success

> ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N _{tot}	N _{rel} [%]	Result	N _{eva}	N _{suc}	S _{rel} [%]
(465) anti-β2-glycoprotein 1 screening		13			13	13	100
Sample A		13			13	13	100
All results	CVP >>>	13	100	Negative			
Sample B		13			13	13	100
All results	CVP >>>	13	100	Positive			
(467) anti-β2-glycoprotein 1 IgG		60			60	59	98
Sample A		60			60	60	100
All results	CVP >>>	60	100	Negative			
Sample B		60			60	59	98
All results		1	1,7	Negative			
	CVP >>>	59	98	Positive			
(468) anti-β2-glycoprotein 1 IgM		59			59	58	98
Sample A		59			59	59	100
All results	CVP >>>	59	100	Negative			
Sample B		59			59	58	98
All results		1	1,7	Negative			
	CVP >>>	58	98	Positive			
(461) anti-cardiolipin screening		15			15	15	100
Sample A		15			15	15	100
All results	CVP >>>	15	100	Negative			
Sample B		15			15	15	100
All results	CVP >>>	15	100	Positive			
(463) anti-cardiolipin IgG		64			64	64	100
Sample A		64			64	64	100
All results	CVP >>>	64	100	Negative			
Sample B		64			64	64	100
All results		>	9	14	Negative		
		>	1	1,6	Inconclusive result (borderline)		
	CVP >>>	54	84	Positive			
(464) anti-cardiolipin IgM		63			63	63	100
Sample A		63			63	63	100
All results	CVP >>>	63	100	Negative			
Sample B		63			63	63	100
All results	CVP >>>	63	100	Positive			